Recent advances in therapeutic strategies for triple-negative breast cancer
Y Li, H Zhang, Y Merkher, L Chen, N Liu… - Journal of hematology & …, 2022 - Springer
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer
L Ding, J Cao, W Lin, H Chen, X **ong, H Ao… - International journal of …, 2020 - mdpi.com
Cyclin-dependent kinases (CDKs) are serine/threonine kinases whose catalytic activities are
regulated by interactions with cyclins and CDK inhibitors (CKIs). CDKs are key regulatory …
regulated by interactions with cyclins and CDK inhibitors (CKIs). CDKs are key regulatory …
Role of STAT3 signaling pathway in breast cancer
J Ma, L Qin, X Li - Cell Communication and Signaling, 2020 - Springer
Breast cancer has grown to be the second leading cause of cancer-related deaths in
women. Only a few treatment options are available for breast cancer due to the widespread …
women. Only a few treatment options are available for breast cancer due to the widespread …
Mechanisms of sensitivity and resistance to CDK4/6 inhibition
M Álvarez-Fernández, M Malumbres - Cancer cell, 2020 - cell.com
Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …
DNA repair pathways in cancer therapy and resistance
L Li, Y Guan, X Chen, J Yang, Y Cheng - Frontiers in pharmacology, 2021 - frontiersin.org
DNA repair pathways are triggered to maintain genetic stability and integrity when
mammalian cells are exposed to endogenous or exogenous DNA-damaging agents. The …
mammalian cells are exposed to endogenous or exogenous DNA-damaging agents. The …
[HTML][HTML] Battling chemoresistance in cancer: root causes and strategies to uproot them
With nearly 10 million deaths, cancer is the leading cause of mortality worldwide. Along with
major key parameters that control cancer treatment management, such as diagnosis …
major key parameters that control cancer treatment management, such as diagnosis …
Targeting janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution
U Bharadwaj, MM Kasembeli, P Robinson… - Pharmacological …, 2020 - Elsevier
Before it was molecularly cloned in 1994, acute-phase response factor or signal transducer
and activator of transcription (STAT) 3 was the focus of intense research into understanding …
and activator of transcription (STAT) 3 was the focus of intense research into understanding …
Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments
Molecular alterations in cancer genes and associated signaling pathways are used to inform
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …
DNA damage response in cancer therapy and resistance: challenges and opportunities
Resistance to chemo-and radiotherapy is a common event among cancer patients and a
reason why new cancer therapies and therapeutic strategies need to be in continuous …
reason why new cancer therapies and therapeutic strategies need to be in continuous …
[HTML][HTML] IL6/STAT3 signaling hijacks estrogen receptor α enhancers to drive breast cancer metastasis
Summary The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a
key oncogenic pathway, which has been thought to be functionally connected to estrogen …
key oncogenic pathway, which has been thought to be functionally connected to estrogen …